TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avenue Therapeutics ( (ATXI) ) has issued an update.
Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its 2025 annual meeting of stockholders. Stockholders must submit proposals for inclusion in the proxy statement by November 28, 2025, to be considered timely, and must comply with the company’s bylaws and the Securities Exchange Act requirements.
Spark’s Take on ATXI Stock
According to Spark, TipRanks’ AI Analyst, ATXI is a Underperform.
Avenue Therapeutics exhibits significant financial and operational challenges, notably with no revenue and ongoing losses, leading to a low financial performance score. The technical indicators point to a bearish trend with potential oversold conditions, but this does not offset the fundamental weaknesses. The valuation is constrained by negative earnings and lack of dividend yield. Overall, the stock holds substantial risks, reflected in its low score.
To see Spark’s full report on ATXI stock, click here.
More about Avenue Therapeutics
Average Trading Volume: 4,765
Technical Sentiment Signal: Sell
Current Market Cap: $2.42M
See more insights into ATXI stock on TipRanks’ Stock Analysis page.